

Pureos Partners welcomes Prof. Dr. Sai Reddy to its team as Venture Partner

Pfäffikon, Switzerland, 1 March 2023

Pureos Partners (Pureos), a venture capital firm dedicated to support private biotech companies developing novel therapies, announced the appointment of Prof. Dr. Sai Reddy as Venture Partner to its team. The fund has USD 205 million under management and has invested in 18 private biotech companies to date. First portfolio companies of Pureos have already gone public or have been acquired.

Sai is a Professor and the principal investigator of the Laboratory for Systems and Synthetic Immunology at the ETH Zurich. Systems and synthetic immunology use quantitative measurements, computational biology, molecular and cellular engineering, and machine learning to describe, understand and reprogram the immune system. His group has developed a number of methods in systems and synthetic immunology. This led to several spin-off companies from his laboratory such as deepCDR Biologics and Engimmune Therapeutics. deepCDR was acquired by Alloy Therapeutics in December 2021. Pureos was the lead investor in Engimmune's seed financing round in 2022.

Commenting on his appointment as Venture Partner, Sai said, "Pureos was instrumental in starting and financing Engimmune out of the ETH Zurich. The fund was actively involved before the company was founded and it has been a pleasure to collaborate with Pureos on Engimmune. As a Venture Partner, I am very pleased to support Pureos with my know-how and experience in the field of immunology to further develop the portfolio and identify new investment opportunities."

Managing Partners of Pureos Dominik Escher stated: "In today's research and development, the aspect of big data, machine learning and artificial intelligence is becoming more and more important to identify the best future drugs against serious diseases. Sai is a world-leading scientist in this fast-growing field, and we are very pleased to have him on board as a new Venture Partner. His knowledge will be of great benefit for Pureos, its portfolio and future investments in biotech companies developing tomorrow's therapies."

###

About Pureos Bioventures

Pureos Partners is a Swiss venture capital firm and the investment adviser of Pureos Bioventures. It invests exclusively in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. The fund's portfolio companies are built on scientific excellence to develop therapies across a broad indication spectrum including oncology, immunology, ophthalmology, rare diseases, and neuroscience. Pureos has built a team with in-depth investment, operating and clinical expertise, that strives to impact patients' lives by advancing innovative treatments for devastating diseases.

For more information visit www.pureosbio.com

Contacts

Dr. Klaus Breiner

Klaus.breiner@pureosbio.com

Dr. Dominik Escher

Dominik.escher@pureosbio.com

Dr. Veronica Gambillara Fonck

Veronica.gambillara@pureosbio.com

Dr. Martin Münchbach

Martin.muenchbach@pureosbio.com

Pureos Partners AG

Churerstrasse 47

8808 Pfäffikon/SZ

Switzerland